Skip to content
Screener

Marcus & Millichap MMI Business Segments — Stock-Based Comp

Similar metrics at other companies

Credo Technology Group Holding Ltd logo
CRDOReportable Segment — Stock-Based Comp
$50.76M+84.6%
Summit Therapeutics logo
SMMTReportable Segment — Stock-Based Comp
$72.79M+556%
QXO, Inc. logo
QXOReportable Segment — Stock-Based Comp
$39.2M+94.1%
Progress Software logo
PRGSReportable Segment — Stock-Based Comp
$20.51M+22.5%
Madrigal Pharmaceuticals, Inc. logo
MDGLReportable Segment — Stock-Based Comp
$28.38M+43.3%
Lifecore Biomedical, Inc. logo
LFCRReportable Segment — Stock-Based Comp
$2.09M

Other financials

Income statement

See full
Revenue$202.9M+17.8%
Operating income$2.2M+124%
Net income$3.9M+135%
EPS (diluted)$0.10+136%

Balance sheet

See full
Cash & equivalents$153.5M+78.6%
Total debt$74.2M-10.0%
Total equity$578.9M-4.7%
Total assets$765.8M-3.3%

Cash flow

See full
Operating cash flow-$27.6M+47.8%
CapEx$945.0K-45.5%
Free cash flow-$30.5M+43.8%

Valuation

See full
Market cap$1.2B+5.2%
Enterprise value$1.12B-1.5%
P/S1.5×-0.1×

Profitability

See full
Gross margin38.1%
Operating margin-9.1%+59.1pp
Net margin-5%-19.8pp
FCF margin10.6%+8.7pp

Returns & leverage

See full
Return on equity-4.9%-44.5pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.6×

Where this comes from

Reported directly by Marcus & Millichap in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The source filing: Marcus & Millichap’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:59 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054439
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Segment net income (loss)3,909(11,035)809(15,457)
Adjustments and reconciling items
Consolidated net income (loss)$3,909$(11,035)$809$(15,457)
Other specified segment disclosures:
Interest income(2)$3,393$4,387$7,417$8,406
Interest expense$140$200$293$387
Other significant noncash items:
Stock-based compensation(3)$6,780$6,223$13,396$12,402

Item 1. Financial Statements

FAQ

What is Marcus & Millichap's business segments — stock-based comp?
Marcus & Millichap (MMI) reported business segments — stock-based comp of $6.78M in Q2 2026.
How has Marcus & Millichap's business segments — stock-based comp changed year-over-year?
Marcus & Millichap's business segments — stock-based comp increased by 9.0% year-over-year, from $6.22M to $6.78M.
What is the long-term trend for Marcus & Millichap's business segments — stock-based comp?
Over 3 years (2022 to 2025), Marcus & Millichap's business segments — stock-based comp has grown at a 11.9% compound annual growth rate (CAGR), from $17.31M to $24.23M.
What does business segments — stock-based comp mean?
This metric represents the total non-cash expense recognized for equity-based awards granted to employees and agents within the reportable business segment. It reflects the cost of aligning the interests of the workforce with shareholders through stock options, restricted stock units, or other equity instruments. Monitoring this figure helps investors assess the impact of long-term incentive programs on segment-level profitability and overall compensation structure.

Ask your AI about Marcus & Millichap's business segments — stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude